Hoth’s GDNF Therapy Restores Cholesterol and Lowers Triglycerides Versus Semaglutide
Treatment with GDNF restored cholesterol to control-diet levels and maintained lower triglycerides versus semaglutide in western diet–fed female mice, demonstrating a favorable lipid profile. Analysis showed stable albumin and alkaline phosphatase, no activation of PPARγ or CD36, and no increase in p62 or pAKT, supporting further MASLD development.
1. Preclinical Efficacy in Western Diet-Fed Female Mice
Treatment with GDNF restored serum cholesterol to control-diet levels and maintained lower triglycerides compared with semaglutide in western diet–fed female mice, demonstrating a favorable lipid profile in an MASLD model.
2. Preservation of Hepatic Autophagy and Stability of Liver Markers
GDNF-treated mice exhibited stable albumin and alkaline phosphatase levels, no increase in p62 accumulation, and unchanged pAKT, PPARγ, and CD36 expression, indicating preserved autophagy and no activation of lipogenic pathways.
3. Support for Continued Development of HT-VA
Positive female-specific preclinical data bolster Hoth’s plan to advance HT-VA into further development for metabolic dysfunction associated with obesity and MASLD.